News Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Investor Alerts

Year All Years 2019 2018 2017 Keywords Go

Advanced Search

Search

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Nov 6, 2019

  Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
• Oct 31, 2019

  Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
• Oct 24, 2019

  Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
• Sep 30, 2019

  Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
• Sep 13, 2019

  Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
• Sep 5, 2019

  Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
• Sep 4, 2019

  Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
• Aug 8, 2019

  /C O R R E C T I O N -- Achieve Life Sciences, Inc./
• Jul 30, 2019

  Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
• Jul 23, 2019

  Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
• Jun 21, 2019

  Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
• Jun 11, 2019

  Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
• Jun 3, 2019

  Achieve Receives $4.2 Million from Exercise of Warrants
• May 30, 2019

  Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
• May 15, 2019

  Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
• May 7, 2019

  Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
• Apr 24, 2019

  Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

  Topline data from ORCA-1 trial expected in the Second Quarter of 2019
• Apr 3, 2019

  Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
• Apr 2, 2019

  Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

  Topline data from ORCA-1 trial expected in the Second Quarter of 2019
• Mar 18, 2019

  Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
• Mar 14, 2019

  Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
• Mar 5, 2019

  Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
• Feb 22, 2019

  Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting
• Feb 20, 2019

  Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation

  Topline data from ORCA-1 trial expected in mid-2019
• Dec 18, 2018

  Achieve Announces Update on Cytisinicline Clinical Development Program
• Nov 7, 2018

  Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update
• Oct 31, 2018

  Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
• Oct 30, 2018

  Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation
• Oct 1, 2018

  Achieve Announces Pricing of $5.6 Million Registered Direct Offering
• Sep 27, 2018

  Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed and Fasted Subjects
• Sep 26, 2018

  Achieve to Present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018
• Sep 18, 2018

  Achieve Announces Positive Cytisine Data Published in International Journal of Drug Policy

  Cytisine Demonstrated Superior Abstinence Rates Compared to Nicotine Replacement Therapy
• Sep 6, 2018

  Achieve Life Sciences Announces Cytisine Data Presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference
• Sep 5, 2018

  Achieve to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 6, 2018
• Aug 8, 2018

  Achieve Reports Financial Results for Second Quarter 2018 and Provides Cytisine Clinical Development Update
• Aug 2, 2018

  Achieve Life Sciences to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 8, 2018
• Jul 11, 2018

  Achieve Life Sciences Announces Advancement of Cytisine Development Program Following Meeting with the FDA
• Jun 26, 2018

  Achieve Announces Positive Cytisine Data Demonstrating No Clinically Significant Drug-Drug Interaction
• Jun 19, 2018

  Achieve Life Sciences, Inc. Announces Closing of a $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
• Jun 15, 2018

  Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
• Jun 11, 2018

  Achieve Announces Publication of Cytisine Data for Next-Generation Cytisine Molecules
• May 23, 2018

  Achieve Life Sciences, Inc. Announces Reverse Stock Split
• May 9, 2018

  Achieve Reports Financial Results for First Quarter 2018
• May 7, 2018

  Achieve Announces Patent Granted on Novel Formulation of Cytisine
• Mar 6, 2018

  Achieve Life Sciences Announces Cytisine Symposium at the 17th World Conference on Tobacco or Health
• Mar 1, 2018

  Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results
• Feb 20, 2018

  Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
• Jan 24, 2018

  Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
• Nov 28, 2017

  Achieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking Cessation
• Nov 14, 2017

  Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects
• Nov 9, 2017

  Achieve Reports Financial Results for Third Quarter 2017
• Nov 8, 2017

  Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017
• Nov 6, 2017

  Achieve Announces Availability of Company Presentation from the Virtual Investor Conference
• Oct 30, 2017

  Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017

  Company invites individual and institutional investors and advisors to attend virtualinvestorconferences.com
• Oct 26, 2017

  Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine
• Oct 4, 2017

  Achieve Announces Advancement of Cytisine Clinical Development Program

  Rapid Progress on Advancing Clinical Program with Commencement of Pharmacokinetic (PK) & Pharmacodynamic (PD) Cytisine Study and Completion of Enrollment in Food Effect PK Study
• Sep 14, 2017

  Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
• Aug 16, 2017

  Achieve Announces Initiation of Cytisine Clinical Development Program
• Aug 10, 2017

  Achieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation Treatment
• Aug 1, 2017

  Achieve Life Sciences Announces Closing of Merger with OncoGenex Pharmaceuticals
• Jun 13, 2017

  Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC

  Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for August 1, 2017
• Mar 8, 2017

  Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")

  Professor Nancy Rigotti, MD, will chair a symposium entitled "Cytisine Update: Moving Research Forward Toward a Globally Affordable Tobacco Cessation Medication"
• Mar 1, 2017

  Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National Institutes of Health to Advance the Development of Cytisine for Smoking Cessation

  Ongoing IND-enabling Non-clinical Program to Support the Use of Cytisine in Smoking Cessation
• Jan 5, 2017

  OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement

  Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization of Cytisine for Smoking Cessation

Show 5102550100 per page